<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>367</serviceExecutionTime><Drug id="79190"><DrugName>filgrastim biosimilar, Fuji Pharma/Gene Techno Science/Mochida</DrugName><DrugNamesKey><Name id="42754937">filgrastim</Name></DrugNamesKey><DrugSynonyms><Name><Value>filgrastim</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>rhG-CSF</Value></Name><Name><Value>filgrastim biosimilar, Fuji Pharma/Gene Techno Science/Mochida</Value></Name><Name><Value>FSK-0808</Value></Name><Name><Value>filgrastim biosimilar (cancer), Gene Techno Science</Value></Name><Name><Value>GBS-001</Value></Name></DrugSynonyms><CompanyOriginator id="1014528">Gene Techno Science Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1014528">Gene Techno Science Co Ltd</Company><Company id="1045871">Fuji Pharma Co Ltd</Company><Company id="18278">Mochida Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1014528" type="Company"><TargetEntity id="5000395529" type="organizationId">Gene Techno Science Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1045871" type="Company"><TargetEntity id="4295879670" type="organizationId">Fuji Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="18278" type="Company"><TargetEntity id="4295877793" type="organizationId">Mochida Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1991" type="ciIndication"><TargetEntity id="D70" type="ICD10"/><TargetEntity id="10029354" type="MEDDRA"/><TargetEntity id="D009503" type="MeSH"/><TargetEntity id="-506284464" type="omicsDisease"/><TargetEntity id="1002" type="siCondition"/></SourceEntity><SourceEntity id="3151" type="Action"><TargetEntity id="1121" type="Mechanism">G-CSF Mimetics</TargetEntity><TargetEntity id="3384" type="Mechanism">G-CSF Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00800" type="ciTarget"><TargetEntity id="36485060414413" type="siTarget">Granulocyte colony-stimulating factor receptor</TargetEntity><TargetEntity id="276" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-09551" type="ciTarget"><TargetEntity id="6716831114403" type="siTarget">Granulocyte colony-stimulating factor</TargetEntity><TargetEntity id="275" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Neutropenia - Japan - May-2013</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1991">Neutropenia</Indication></IndicationsPrimary><ActionsPrimary><Action id="52970">GCSF ligand</Action><Action id="3151">GCSF receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action><Action id="7759">Neutrophil stimulator</Action></ActionsSecondary><Technologies><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology><Technology id="962">Biosimilar product</Technology></Technologies><LastModificationDate>2016-01-14T13:05:34.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-17T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1045871" linkType="Company"&gt;Fuji Pharma&lt;/ulink&gt; and &lt;ulink linkID="18278" linkType="Company"&gt;Mochida&lt;/ulink&gt; have developed and launched FSK-0808 (GBS-001), a biosimilar version of the recombinant human G-CSF (rhG-CSF) analog &lt;ulink linkID="3130" linkType="Drug"&gt;filgrastim&lt;/ulink&gt;, discovered by Fuji Pharma and &lt;ulink linkID="1014528" linkType="Company"&gt;Gene Techno Science&lt;/ulink&gt;, for the prevention of chemotherapy-induced neutropenia [&lt;ulink linkID="1131407" linkType="Reference"&gt;1131407&lt;/ulink&gt;], [&lt;ulink linkID="1224463" linkType="Reference"&gt;1224463&lt;/ulink&gt;], [&lt;ulink linkID="1431651" linkType="Reference"&gt;1431651&lt;/ulink&gt;], [&lt;ulink linkID="1516999" linkType="Reference"&gt;1516999&lt;/ulink&gt;]. In May 2013, the drug was launched in Japan by Gene Techno Sciences [&lt;ulink linkID="1516999" linkType="Reference"&gt;1516999&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2011, Fuji Pharma and Mochida submitted an application for FSK-0808 in Japan [&lt;ulink linkID="1306772" linkType="Reference"&gt;1306772&lt;/ulink&gt;]; in October 2012, the Pharmaceutical Affairs and Food Sanitation Council's Second Committee on Drugs was to review the application at a meeting on October 31, 2012 [&lt;ulink linkID="1338417" linkType="Reference"&gt;1338417&lt;/ulink&gt;].  In November 2012, Mochida received an approval for FSK-0808 at  75, 150 and 300 microg for neutropenia. At that time, the company reported that the agent would be marketed after the listing in NHI price [&lt;ulink linkID="1342932" linkType="Reference"&gt;1342932&lt;/ulink&gt;]. In December 2012, the drug was expected to be launched in May to June 2013 [&lt;ulink linkID="1352045" linkType="Reference"&gt;1352045&lt;/ulink&gt;]; in May 2013, the drug was launched [&lt;ulink linkID="1431651" linkType="Reference"&gt;1431651&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2012, the biosimilar was listed as  being in phase III development in Gene Techno's pipeline [&lt;ulink linkID="1313253" linkType="Reference"&gt;1313253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, FSK-0808 was listed as being in phase II/III development [&lt;ulink linkID="1131407" linkType="Reference"&gt;1131407&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2010, Fuji Pharma and Mochida agreed to collaborate on the clinical development of a biosimilar version of rhG-CSF [&lt;ulink linkID="1224463" linkType="Reference"&gt;1224463&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By February 2010, Fuji Pharma and Gene Techno Science had codeveloped a rhG-CSF [&lt;ulink linkID="1224463" linkType="Reference"&gt;1224463&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1045871">Fuji Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1431651" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014528">Gene Techno Science Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1516999" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2013-05-31T00:00:00.000Z</StatusDate><Source id="1431651" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1045871">Fuji Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2010-02-02T00:00:00.000Z</StatusDate><Source id="1224463" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2010-09-15T00:00:00.000Z</StatusDate><Source id="1131407" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045871">Fuji Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2010-09-15T00:00:00.000Z</StatusDate><Source id="1131407" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2011-12-28T00:00:00.000Z</StatusDate><Source id="1306772" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045871">Fuji Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2011-12-28T00:00:00.000Z</StatusDate><Source id="1306772" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2012-11-21T00:00:00.000Z</StatusDate><Source id="1342932" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045871">Fuji Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2012-11-21T00:00:00.000Z</StatusDate><Source id="1342932" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014528">Gene Techno Science Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2010-02-02T00:00:00.000Z</StatusDate><Source id="1224463" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014528">Gene Techno Science Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1991">Neutropenia</Indication><StatusDate>2012-08-03T00:00:00.000Z</StatusDate><Source id="1313253" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00800"><Name>GCSF receptor</Name><SwissprotNumbers><Swissprot>P40223</Swissprot><Swissprot>Q99062</Swissprot></SwissprotNumbers></Target><Target id="PTGT-09551"><Name>GCSF ligand</Name><SwissprotNumbers><Swissprot>O02708</Swissprot><Swissprot>O02837</Swissprot><Swissprot>P09919</Swissprot><Swissprot>P09920</Swissprot><Swissprot>P35833</Swissprot><Swissprot>P35834</Swissprot><Swissprot>Q28746</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1727024" linkType="reference" linkID="1727024"&gt;1727024&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1014528">Gene Techno Science Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1045871">Fuji Pharma Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18278">Mochida Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><Deals><Deal id="136384" title="Gene Techno Science and Fuji Pharma to codevelop and copromote rhG-CSF products "/><Deal id="136385" title="Mochida Pharmaceutical and Fuji Pharma to collaborate on the clinical development of rhG-CSF and biosimilar G-CSF"/><Deal id="155766" title="Mochida to negotiate a license for Gene Techno's biosimilar products against cancer "/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>